west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "Portal vein" 21 results
  • Treatment Experience of Type Ⅳ Hilar Cholangiocarcinoma

    Objective To explore primary surgical treatment experience of typeⅣ hilar cholangiocarcinoma. Methods From April 2008 to April 2011,20 patients with type Ⅳ hilar cholangiocarcinoma were enrolled into the same surgical group in Department of Hepatobiliary and Pancreatic Surgery of West China Hospital of Sichuan University.The intra- and post-operative results were analyzed.Results The total resection rate was 75%,which was consisted of 10 cases of radical excision and 5 cases of non-radical excision.Seven patients received left hepatic trisegmentectomy and caudate lobe resection including anterior and posterior right hepatic duct reconstruction,hepatojejunostomy,and Roux-en-Y jejunojejunostomy.Six patients received enlarged left hepatic trisegmentectomy and caudate lobe resection including left intrahepatic and extrahepatic duct reconstruction,hepatojejunostomy,and Roux-en-Y jejunojejunostomy. Two patients received quadrate lobe resection including two cholangioenterostomies after anterior and posterior right hepatic duct reconstruction,and left intrahepatic and extrahepatic duct reconstruction.After percutaneous transhepatic cholangial drainage (PTCD) and portal vein embolization (PVE),two patients with total bilirubins >400 mmol/L received radical excision and non-radical excision,respectively.Three patients only received PTCD during operation due to wide liver and distant metastasis,and two patients received T tube drainage during operation and postoperative PTCD due to left and right portal vein involvement. All 15 patients who received lesion resection survived more than one year, whereas another five patients whose lesions can not been resec ted only survived from 3 to 6 months with the mean of 4.2 months.No death occurred during the perioperative period. Conclusions For patients with type Ⅳ hilar cholangiocarcinoma, preoperative evaluation and tumor resection shall conducted so as to relieve obstruction of biliary tract,otherwise PTCD and PVE prior to the final lesion resection shall be performed.

    Release date: Export PDF Favorites Scan
  • Clinical Application of Multi-Slice Spiral CT in Portal Vein Imaging

    Objective To study the clinical significance of multi-slice spiral CT in portal vein imaging. Methods One hundred and thirty seven cases underwent enhanced scan with GE Light SpeedQX/i4 CT scanner were collected, including 41 cases of liver cancer, 20 cases of hepatic cirrhosis, 21 cases of cavernous hemangioma of liver, 9 cases of hepatic abscess, 6 cases of carcinoma of gallbladder, 14 cases of cholangiocarcinoma, 16 cases of pancreatic carcinoma, and 5 cases in normal. The results of portal vein images were reconstructed with three-dimensional software and analyzed. Results In 109 cases, portal vein, cranial mesenteric vein, and splenic vein were demonstrated successfully in the stage of portal vein: volume rendering images were clear in 84 cases, and maximum intensity projection images and multiplanar reconstruction images were clear in 109 cases. Forty-five cases of portal hypertension, 18 cases of opened collateral circulation, 15 cases of portal vein tumor thrombus, 1 case of splenic vein tumor thrombus, and 6 cases of large cavernous hemangioma were demonstrated successfully. Conclusion The portal vein imaging with multi-slice spiral CT can show the dissection and lesions of portal vein and its branches clearly, and can provide the clinical evidence for clinicians to formulate a treatment plan correctly.

    Release date:2016-09-08 10:49 Export PDF Favorites Scan
  • Significance of Expression of Platelet Derived Growth Factor and Survivin of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

    Objective To investigate the expressions of platelet derived growth factor (PDGF) and survivin in hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) and to evaluate the relationships among the expressions of PDGF, survivin and the proliferation of cancer cells. Methods The expression of PDGF mRNA in 16 cases in HCC with PVTT group was observed by in situ hybridization and the results were compared with that in HCC tissue group. The expressions of PDGF and survivin protein in 36 cases in HCC with PVTT group were detected with immunohistochemistry and it was found that there was a correlation between them. Flow cytometry (FCM) was used to measure the proliferation of cancer cells and it was also used to analyze the relations among PDGF, survivin and the proliferation of cancer cells. Results The expression level of PDGF mRNA in HCC with PVTT group was significantly higher than that in HCC tissue group (P<0.01). There was a positive correlation between the expressions of PDGF and survivin protein in HCC with PVTT (P<0.01). The degree of proliferation of cancer cells in PDGF and survivin protein positive group was significantly higher than that in negative group (P<0.01). Conclusion PDGF and survivin gene over-expressed in HCC with PVTT group and there is a positive correlation between the expressions of PDGF and survivin protein. The proliferation of cancer cells increases as the expressions of PDGF and survivin increase.

    Release date:2016-08-28 04:08 Export PDF Favorites Scan
  • The Relationship Between the Apoptosis Hepatocyte and Its Genic Mediation and the Ischemia of Portal Vein

    ObjectiveTo introduce the relationship between the apoptosis hepatocyte and its genic mediation and the ischemia of portal vein. MethodsThe combination of related literatures and our research findings were made.ResultsPortal vein ischemia may induced hepatocyte apoptosis, p53 and bcl2 gene alternatively adjust hepatocyte apoptosis. Expression of p53 gene is enhanced in hepatic tissue when hepatocyte apoptosis is not obvious, but after 24-72 h of portal vein ischemia, when hepatocyte apoptosis is obvious, enhanced expression of p53 gene or reduced expression of bcl2 gene occur. There exists close relationship between portal vein ischemia and hepatocyte apoptosis. Conclusion Apoptosis hepatocyte is involved in organic atrophy after ischemia of portal vein, and p53 and bcl2 gene alternatively adjust hepatocyte apoptosis. At present, the mechanism of apoptosis of hepatocyte induced by ischemia of portal vein is not clear, which needs further study.

    Release date:2016-08-28 04:49 Export PDF Favorites Scan
  • A RELATIONSHIP BETWEEN INTRA-BILIARY TRACT PRESSURE,PORTAL VEINOUS FLOW RATE AND INTERLEUKIN-2,SOLUBLE INTERLEUKIN-2 RECEPTOR,T LYMPHOCYTE SUBPOPULATION IN OBSTRUCTIVE JAUNDICE

    To investigate the cause of septicemia in patients with obstructive jaundice,the correlationship between intra-biliary tract pressure(IBTP),portal veinous flow rate(PVFR)and interleukin-2(IL-2),soluble interleukin-2 receptor(sIL-2R),T lymphocyte subpopulation in patient with obstructive jaundice(Group A)has been studied.Group A was subdivided into A1,emergency operation group;A2,elective surgery group;A3,patient’s age over 60 years and A4,age under 60.Ninety patients with simple gallstone(Group B)were also tested as a contrast.The result showed that of all Group A,CD3+,CD4+,CD8+ before operation were much lower than those 10 days after operation(Plt;0.05 or Plt;0.01),while the postoperative sIL-2R was significantly higher than that of 10 days after operation(Plt;0.01),in Group A1,emergency surgery,the preoperative sIL-2R was much more higher than that in others of the jaundice group(Plt;0.01).Corralation analysis showed IBTP was negatively corralated to IL-2,CD3+,CD4+,CD8+,but it had positive correlation with sIL-2R(Plt;0.01).PVFR was positively correlated to IL-2(Plt;0.01).These indicate that obstructive jaundice with infection is closely related to the decreased host immunity.

    Release date:2016-08-29 03:24 Export PDF Favorites Scan
  • The Progress of Treatment for Primary Liver Cancer with Portal Vein Tumor Thrombus

    Objective To improve the prognosis of primary liver cancer with portal vein tumor thrombus (PVTT), the progress of treatment for primary liver cancer with PVTT was reviewed. Methods The therapeutic approach and its efficacy for primary liver cancer with PVTT were summarized by literature search within recent years. Results PVTT is a common complication of primary liver cancer, the therapeutic approach are surgical resection, transcatheter arterial chemoembolization (TACE), intraportal venous therapy, radiotherapy, ablation therapy, molecular targeted therapy, etc. The excision rate for primary liver cancer with PVTT is low, the treatment is difficult and the outcome is dismal. It remains a poor prognosis at present, and the therapeutic effect need to be promoted. Conclusions The main treatment for primary liver cancer with PVTT should be surgical excision combine with other multidisciplinary comprehensive treatment to improve the survival in patients with PVTT, moreover, the therapeutic approach should be individualized and sequentially according to the patient’s condition and the type of PVTT.

    Release date:2016-09-08 10:36 Export PDF Favorites Scan
  • Compare The Effects of Two Chemotherapeutic Patterns after Hepatectomy of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

    Objective To compare the effect of two chemotherapeutic patterns after hepatectomy of hepatocellular carcinoma (HCC) with portal vein tumor thrombi(PVTT). Methods The clinical data of 51 HCC patients with PVTT who were treated in our department from June 2006 to December 2011 were analyzed retrospectively. Fifty-one HCC patients with PVTT who were performed hepatectomy and treatment of antivirus and improve immune were divided into two groups according to chemotherapeutic patterns after operation: portal vein infusion drug deliver system (PVIDDS)group (n=19) and transcatheter arterial chemoembolization(TACE) group(n=32),and to compare the treatment effect of the two groups. Results The recurrence rate of 1-month, 1-year,3-year, and 5-year after operation in TACE group was 3.1%(1/32),46.9%(15/32),84.4%(27/32), and 100%(32/32),respectively. And in PVIDDS group, which was 5.3%(1/19),52.6%(10/19),100%(19/19), and 100%(19/19),respectively. There were no differences in recurrence rate of 1-month, 1-year, and 5-year after operation in two groups(P>0.05). Recurrence rate of 3-year after operation in TACE group was lower than that in PVIDDS group(P<0.05). There were no differences in medial survival time(17.1 months vs.15.9 months), survival rate of 1-year(93.8% vs.94.7%) and 3-year(40.6% vs. 36.8%) after operation in TACE group and PVIDDS group(P>0.05). Survival rate of 5-year after operation in TACE group was higher than that in PVIDDS group(21.9% vs.0, P<0.05). The rate of complication in TACE group was lower than that in PVIDDS group(65.6% vs.94.7%,P<0.05). Conclusions If the HCC patients with PVTT could endure operation,surgical resection should be considered firstly,furthermore antivirus treatment, improving immune,and chemotherapy should be considered after operation. The effect of TACE is better than PVIDDS.

    Release date:2016-09-08 10:36 Export PDF Favorites Scan
  • Analysis of Surgical Treatment for Primary Liver Cancer with Portal Vein Tumor Thrombus

    Objective To explore the curative effect of surgical treatment for primary liver cancer with portal vein tumor thrombus(PVTT). Methods The clinical data of 227 patients who were performed surgical treatment because of primary liver cancer with PVTT were analyzed retrospectively. Results Two hundreds and seventeen cases were performed surgical resection, 14 cases died from postoperative complications. The median survival time was 17.7 months, and the l-, 2-, 3-, and 5-year survival rates were 61.9%, 37.2%, 21.7%, and 4.0% respectively. There were 40 cases with PVTT ofⅠtype, the l-, 2-, 3-, and 5-year survival rates were 82.3% , 61.7%, 38.6%, and 6.6% respectively,which was obviously higher than those with PVTT of Ⅱ type (n=129, 61.1%, 34.3%, 20.8%, and 5.3%) and PVTT of Ⅲ type (n=48, 46.8%, 24.0%, 9.6%, and 0), P<0.05. There were 84 cases whose PVTT and tumor were resected together, the l-, 2-, 3-, and 5-year survival rates were 67.3%, 43.2%, 28.1%, and 7.9% respectively,which were obviously higher than those patients whose PVTT were removed from cross-section of liver (n= 85, 65.1%, 38.8%, 22.3%, and 3.4%) and patients whose PVTT were removed by cutting the portal vein (n=48, 46.8%, 24.0%, 9.6%, and 0), P<0.05. The l-, 2-, 3-, and 5-year survival rates of 76 cases who received postoperative therapy of TACE/TAI were 75.3%, 53.2%, 33.1%, and 5.7% respectively, which were obviously higher than those patients who were not received any postoperative therapy (n=141, 54.8%, 29.1%, 15.9%, and 3.2%), P<0.05. Conclusions Surgical treatment is an effective treatment for primary liver cancer with PVTT. Surgery should strive for resecting the tumor and PVTT together, and postoperative therapy of TACE/TAI may have a favorable effect on the long term survival rate.

    Release date:2016-09-08 10:37 Export PDF Favorites Scan
  • Clinical Analysis of Portal Vein Thrombosis after Splenectomy

    Objective To explore the cause, diagnosis, and treatment methods of portal vein thrombosis (PVT) after splenectomy. Methods The clinical data of 29 patients who were got splenectomy because of portal hypertension or traumatic splenic rupture from August 2002 to August 2008 in our hospital were analyzed retrospectively. Results Tweenty-seven patients with PVT were treated successfully, whose thrombi were absorbed completely or partially. One case died of peritonitis,septic shock,and multiple organ failure. One case died of hematemesis, hepatic coma,and multiple organ failure. Tweenty-four patients were followed up, the follow-up time was 0.5 to 3 years, the average was 2 years. Two cases died of massive hemorrhage, 1 case died of hepatic encephalopathy,and 1 case died of liver failure. Two cases occurred deep venous thrombosis in one year after treatment, and the remaining patients had no recurrence of venous thrombosis. Conclusions PVT have some connection with the raise of blood platelet and the hemodynamic changes of the portal vein system after splenectomy. Standardization of operation, early diagnosis, early line anticoagulant,and antiplatelet adhesion therapy are effective way to prevent and treat PVT.

    Release date:2016-09-08 10:38 Export PDF Favorites Scan
  • Study on Significance and Expression of Transforming Growth Factor α and β1 after 90% Portal Vein Ligation in Rats

    Objective To investigate the expressions of transforming growth factor (TGF) -α and -β1 after 90% portal branch ligation (PBL) in rats. Methods Ninety-six SD rats were randomly divided into sham operation group and portal vein branches ligation group. The weight of both ligated and unligated lobes of liver were measured on 0.5, 1, 3, 5, 7, 14, 21, and 28 d after operation. The morphological changes of the unligated liver lobes were observed by microscope. The expressions of proliferating cell nuclear antigen (PCNA), TGF-α, and TGF-β1 of the unligated liver lobes were detected by immunohistochemistry. Results After the ligation of 90% portal vein branches, hepatic lobe at the ligated side diminished progressively after ligation, whereas the lobes of the unligated side underwent compensatory regeneration. The ratio of unligated lobes weight to the whole liver increased slowly within 1 d, speeded up significantly during 1-5 d period, increased slowly on 5 d, and reached plateau phase on 7 d after operation. The expressions of PCNA protein markedly increased within 0.5-3 d (Plt;0.01), which reached the peak on 5 d and decreased slightly on 7 d after operation, but still higher than sham operation group level, and then gradually returned to the level of sham operation group lately. The expressions of TGF-α and TGF-β1 in the unligated liver lobes markedly increased on 0.5 d, and reached the peak on 3 d and 1 d respectively, and then gradually returned to the level of sham operation group in 7-28 d after operation. Conclusion Ligation of 90% portal branches can induce active regeneration of unligated liver lobes in rats, whose initiation and proliferation are involved in the expressions of TGF-α and TGF-β1 protein.

    Release date:2016-09-08 10:54 Export PDF Favorites Scan
3 pages Previous 1 2 3 Next

Format

Content